Source: Υπουργείο Υγείας (CY) Revision Year: 2020 Publisher: M. K. Stavrinos ltd., 3 Irakleous Str., 1046 Nicosia, Cyprus Tel.: 22434490, Fax: 22434485, E-mail: mkstavco@cytanet.com.cy
Mydoflex tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablets. |
The active substance of both products is tolperisone (INN) hydrochloride.
Mydoflex tablets containing 150 mg tolperisone hydrochloride.
For excipients, see §6.1.
| Active Ingredient | Description | |
|---|---|---|
| Tolperisone |
As a skeletal muscle relaxant whose prototype is mephenesine, tolperisone induces ataxia and muscle weakness in animal models by acting on the central nervous system at the spinal level. In fact it inhibits polysynaptic and monosynaptic reflexes with little action on non-reflex muscle response and without potentiating the phenobarbital sleep. |
| List of Excipients |
|---|
|
Tablet core: Citric acid anhydrous Coating: Polyvinyl alcohol-part. hydrolysed |
Aluminium/blister.
Pack sizes: 30 tablets.
M. K. Stavrinos ltd., 3 Irakleous Str., 1046 Nicosia, Cyprus
Tel.: 22434490, Fax: 22434485, E-mail: mkstavco@cytanet.com.cy
16780
15 November 1996.
| Drug | Countries | |
|---|---|---|
| MYDOFLEX | Cyprus |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
